Breast cancer trial aims to spare women unnecessary surgery

NCT ID NCT07498400

Ongoing Disease control Sponsor: Xijing Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at whether women with triple-negative or HER2-positive breast cancer who have a complete response to chemotherapy can safely skip sentinel lymph node biopsy. The trial will compare standard surgery plus biopsy versus surgery alone, measuring how often cancer returns in the armpit area over three years. The goal is to reduce side effects like lymphedema and pain while maintaining safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Exemption of sentinel lymph node biopsy (procedure)
What this could lead to: If successful, this could allow many women with triple-negative or HER2-positive breast cancer to avoid an extra surgical procedure, reducing side effects like arm swelling and pain.
What could go wrong: This is a relatively small, early-phase study (216 participants). It is not yet clear if skipping the biopsy will lead to a higher chance of cancer returning in the lymph nodes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER BREAST CANCER (TRIPLE NEGATIVE BREAST CANCER (TNBC))

Contacts and locations

Locations

Xijing Hospital

Xi'an, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.